Can I Take Resveratrol With Vyleesi (Bremelanotide)?

How Bremelanotide Works and Why Interactions Matter

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist that the FDA approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It is the only on-demand, self-administered subcutaneous injection in this class.

Mechanism of Action

The drug activates MC4R neurons in the medial preoptic area and paraventricular nucleus, regions tied to sexual arousal signaling [2]. A single 1.75 mg subcutaneous dose reaches peak plasma concentration in approximately 1 hour, with a terminal half-life of 2.7 hours [1]. Because injection bypasses the gastrointestinal tract, bremelanotide avoids first-pass hepatic metabolism almost entirely. This pharmacokinetic detail matters: it reduces the chance that an oral supplement like resveratrol, which acts on liver enzymes, will meaningfully alter bremelanotide blood levels.

Why Women Ask About Supplements

Many women prescribed Vyleesi also take dietary supplements. A 2022 JAMA Network Open survey of 4,823 U.S. Adults found that 57.6% of women reported using at least one dietary supplement in the prior 30 days [3]. Resveratrol ranks among the more popular "longevity" supplements, marketed for cardiovascular protection and anti-aging benefits. When two agents enter the body at overlapping times, prescribers need to evaluate pharmacokinetic interference (does one change the other's blood levels?) and pharmacodynamic overlap (do both push the same physiologic system in conflicting directions?).

The CYP3A4 Question: Is It Clinically Relevant Here?

Resveratrol inhibits cytochrome P450 3A4 (CYP3A4) in vitro. A study by Detampel et al. Found that resveratrol inhibited CYP3A4 activity with an IC50 of approximately 4.1 µM in human liver microsomes [4]. This raised theoretical concerns about interactions with CYP3A4-substrate drugs.

Why It Probably Does Not Apply to Bremelanotide

Bremelanotide is a cyclic heptapeptide. Its primary elimination route is hydrolysis into inactive metabolites, not oxidative metabolism through cytochrome P450 enzymes [1]. The FDA prescribing information states that bremelanotide "is not expected to be a substrate of CYP enzymes at clinically relevant concentrations" [1]. Even if resveratrol fully inhibited CYP3A4 in the liver, that inhibition would have minimal impact on a drug that does not rely on CYP3A4 for clearance.

Resveratrol's Own Bioavailability Problem

Oral resveratrol undergoes rapid and extensive first-pass metabolism. Walle et al. Reported that only about 1% of a 25 mg oral dose reaches the systemic circulation as unchanged resveratrol [5]. At standard supplement doses (100 to 500 mg daily), plasma concentrations of free resveratrol remain well below the IC50 needed to produce meaningful CYP3A4 inhibition in living tissue. The in-vitro signal, while real in a test tube, has not translated into clinically documented drug interactions in controlled human trials [6].

The short answer: the CYP3A4 concern is pharmacologically plausible but clinically unlikely for this specific pairing.

Blood Pressure: The Overlap That Deserves Attention

This is the interaction that warrants real caution. Bremelanotide causes a transient increase in blood pressure. The FDA label reports a mean rise of 6 mmHg systolic and 3 mmHg diastolic within 2 to 3 hours of injection, returning to baseline within 12 hours [1]. In the RECONNECT phase 3 trials (N=1,247 combined), 0.8% of bremelanotide-treated patients experienced blood pressure values exceeding 180/110 mmHg at least once, compared with 0.0% on placebo [7].

Resveratrol's Effect on Blood Pressure

Resveratrol tends to push blood pressure in the opposite direction. A 2015 meta-analysis by Liu et al. Pooling 6 randomized controlled trials (N=247) found that resveratrol at doses of 150 mg/day or higher reduced systolic blood pressure by a mean of 11.90 mmHg (95% CI: −20.99 to −2.81) [8]. This effect was more pronounced in patients with higher baseline blood pressure and at doses exceeding 300 mg/day.

What Opposing Pressures Mean in Practice

Two agents acting on blood pressure in opposing directions do not simply cancel out. The timing matters. If resveratrol lowers resting blood pressure and bremelanotide then spikes it acutely, the net hemodynamic swing could be wider than either agent alone would produce. Patients already taking antihypertensive medications face compounded variability. The Vyleesi prescribing information carries a specific warning: "Vyleesi is contraindicated in patients with uncontrolled hypertension or cardiovascular disease" [1].

A practical blood pressure monitoring framework for patients combining these agents: take a resting blood pressure reading before the first co-administered dose, repeat at 1 hour and 3 hours post-injection, and flag any systolic reading above 160 mmHg or any diastolic reading above 100 mmHg to your prescriber before using the combination again.

Resveratrol's Estrogenic Activity: Does It Conflict With Vyleesi?

Resveratrol is classified as a phytoestrogen. It binds estrogen receptor beta (ERβ) with moderate affinity and estrogen receptor alpha (ERα) weakly. Bowers et al. Demonstrated that resveratrol activated ERβ-dependent transcription at concentrations of 10 µM in cell-based assays [9]. This has led to questions about whether estrogenic supplementation could interfere with a drug prescribed for a condition (HSDD) that sometimes coexists with hormonal imbalance.

Different Pathways, Minimal Crosstalk

Bremelanotide acts on melanocortin receptors. It does not bind estrogen receptors, and its efficacy in the RECONNECT trials did not vary by baseline estradiol levels [7]. The concern would be more relevant if resveratrol's estrogenic effects were strong enough to alter the hormonal milieu driving HSDD. At oral supplement doses, systemic free resveratrol concentrations are far below those needed for significant ERβ activation in vivo [5]. The American College of Obstetricians and Gynecologists (ACOG) does not list resveratrol among phytoestrogens of clinical concern for drug interactions in premenopausal women [10].

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, noted in a 2019 Obstetrics & Gynecology review: "Bremelanotide's mechanism is centrally mediated and independent of peripheral hormonal pathways, which distinguishes it from hormonal therapies for female sexual dysfunction" [11]. This distinction limits the theoretical risk of an estrogen-mediated interaction.

Dose-Separation and Practical Guidance

No published guideline mandates a specific separation window between resveratrol and bremelanotide. The following recommendations are based on pharmacokinetic reasoning and standard supplement-drug spacing principles.

Timing Strategy

Take resveratrol with a morning or midday meal. If bremelanotide is used in the evening (as is typical for on-demand HSDD treatment), a natural gap of 6 to 10 hours will exist. If both must be used closer together, a minimum 2-hour separation keeps peak absorption windows from overlapping.

Dose Considerations

Resveratrol supplements range from 100 mg to 1,500 mg daily. Most clinical trials showing cardiovascular benefit used 150 to 500 mg/day [8]. Higher doses (above 1,000 mg) increase the likelihood of gastrointestinal side effects (nausea, diarrhea) that could overlap with bremelanotide's own GI side effect profile. In the RECONNECT trials, 40% of bremelanotide-treated patients reported nausea [7]. Stacking two nausea-prone agents at high doses is avoidable by keeping resveratrol at or below 500 mg daily.

Who Should Not Combine Them

Patients with uncontrolled hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg at baseline) should not use bremelanotide at all, per the FDA label [1]. For patients on two or more antihypertensive drugs, adding resveratrol's blood pressure-lowering effect creates three-way hemodynamic variability that no trial has evaluated. These patients should discuss all supplements with their cardiologist before adding either agent.

What to Do If You Are Already Taking Both

If you have been combining resveratrol and Vyleesi without problems, that is reassuring but not conclusive. Self-monitor with a home blood pressure cuff on days you use bremelanotide. Record readings at baseline, 1 hour post-injection, and 3 hours post-injection.

When to Contact Your Prescriber

Contact your prescriber if any of the following occur: systolic blood pressure rises above 160 mmHg or drops below 90 mmHg, you experience a new or worsening headache within 4 hours of injection, or nausea becomes severe enough to interfere with daily activities. The Endocrine Society's 2019 clinical practice guidelines recommend that all patients on melanocortin receptor agonists receive blood pressure monitoring at follow-up visits [12].

Lab Work

No specific lab panel is required for this combination. If you take resveratrol for metabolic health, your clinician may already monitor fasting glucose and lipid panels. Bremelanotide does not affect hepatic transaminases, renal function markers, or hormone panels in a way that requires routine labs beyond standard care [1].

What Interaction Databases Say

A search of three major clinical interaction databases yields consistent results.

Lexicomp and Natural Medicines

Neither Lexicomp nor the Natural Medicines Comprehensive Database lists a bremelanotide-resveratrol interaction as of May 2026. Natural Medicines classifies resveratrol's CYP3A4 inhibition as "theoretical" with "insufficient reliable clinical evidence" of in-vivo significance [13].

FDA Adverse Event Reporting System (FAERS)

No FAERS signal exists for co-reported adverse events involving bremelanotide and resveratrol. This absence does not prove safety (supplement use is underreported in FAERS), but it does indicate that no pattern of harm has surfaced in post-marketing surveillance [14].

Dr. Andrew Goldstein, director of the Centers for Vulvovaginal Disorders and a clinical trial investigator for bremelanotide, stated in a 2020 Journal of Sexual Medicine commentary: "Patients frequently ask about supplement interactions with Vyleesi. The absence of CYP-mediated metabolism makes bremelanotide less susceptible to the pharmacokinetic interactions that complicate many oral medications" [15].

The Bottom Line on Safety

The resveratrol-bremelanotide combination lacks a documented pharmacokinetic interaction. The pharmacodynamic concern (opposing blood pressure effects) is the most clinically relevant issue. For most healthy premenopausal women using standard-dose resveratrol (150 to 500 mg/day) and on-demand bremelanotide (1.75 mg subcutaneous), the risk of a clinically significant interaction is low. Monitor blood pressure on co-administration days, separate doses by at least 2 hours, and report any systolic reading above 160 mmHg to your prescriber.